Fujian Haixi Pharmaceuticals Co., Ltd. (SEHK: 2637)
Salud · Farmacéuticas · CN
156,00 HK$
-0,32 % hoy · +18,2 % 1 año
Fujian Haixi Pharmaceuticals Co., Ltd. (SEHK: 2637) opera en la industria de farmacéuticas dentro del sector salud. Su valor en bolsa es de 1,57 mil M $ y tiene 200 empleados.
En los últimos doce meses la acción ha subido un 18,2 % y ha cotizado entre 121,60 y 302,40.
Tweenvest puntúa a Fujian Haixi Pharmaceuticals Co., Ltd. en cuatro factores: calidad 95/100, valor 58/100. Su punto más fuerte es calidad.
Evolución de la cotización de 2637
Cifras clave
- Capitalización
- 1,57 mil M $
- Ingresos (últ. 12 m)
- 87,43 M $
- PER
- 67,67
- BPA
- 2,58
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 302,40 HK$
- Mínimo 52 semanas
- 121,60 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 78,71 M
- Empleados
- 200
- Próximos resultados
- —
Sobre Fujian Haixi Pharmaceuticals Co., Ltd.
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo, a generic of cinacalcet hydrochloride tablets; and Saixifu, a generic of hydroxychloroquine sulfate tablets. Further, it provides Haibiping, a generic of valsartan and amlodipine tablets; Anyoufan, a generic of escitalopram oxalate tablets; Haikexi, a generic of valsartan tablets; Anfeiping, a generic of diclofenac sodium enteric-coated tablets; and Jishuning, a generic of cetirizine hydrochloride oral solution. Additionally, the company's pipeline includes C019199, a drug candidate targeting the modulation of the immunosuppressive tumor microenvironment for the treatment of advanced osteosarcoma, which has completed phase II clinical trials; HXP056, an oral small-molecule drug designed to treat retinopathy-related diseases, which has completed phase I clinical trial; HXP089, an oral small-molecule drug targeting glioblastoma multiforme; and HXP090, an oral small-molecule drug designed specifically targeting idiopathic pulmonary fibrosis. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms. Fujian Haixi Pharmaceuticals Co., Ltd. was incorporated in 2012 and is based in Fuzhou, China.
- ISIN
- CNE100007515
- Fundada en
- 2012
- Cotiza desde
- 8 dic 2025
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de farmacéuticas
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Shanghai Shyndec Pharmaceutical Co., Ltd.SHSE: 600420 | 1,60 mil M $ | 7,97 CN¥ | -1,24 % |
| Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287 | 1,60 mil M $ | 18,79 CN¥ | +0,54 % |
| Braveheart Bio, Inc.NasdaqGM: BRVE | 1,59 mil M $ | 19,49 $ | -0,66 % |
| Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572 | 1,57 mil M $ | 4,12 CN¥ | -0,48 % |
| Vigonvita Life Sciences Co., Ltd.SEHK: 2630 | 1,55 mil M $ | 72,65 HK$ | -3,13 % |
| Marksans Pharma LimitedNSEI: MARKSANS | 1,53 mil M $ | 318,50 Rs | -0,47 % |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | 1,51 mil M $ | 43,40 CN¥ | -5,28 % |
| Xiamen Kingdomway Group CompanySZSE: 002626 | 1,51 mil M $ | 16,94 CN¥ | +0,89 % |